Effect of rituximab on serum hepcidin, sCD40L, PDGF-BB and LDH levels in patients with malignant lymphadenoma
- VernacularTitle:利妥昔单抗对恶性淋巴瘤患者血清hepcidin、sCD40 L、PDGF-BB与LDH水平的影响
- Author:
Huangyang YE
;
Xiaojun LV
;
Yinghong ZHANG
;
Yonghua YAO
- Publication Type:Journal Article
- Keywords:
rituximab;
soluble CD40 ligands;
platelet derived growth factor-BB;
lactic dehydrogenase
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(9):136-137,140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of rituximab on serum hepcidin (Hepc), soluble CD40 ligands (sCD40L), platelet derived growth factor-BB (PDGF-BB) and lactate dehydrogenase (LDH) in patients with malignant lymphadenoma.Methods 52 patients with malignant lymphoma from the hospital were randomly divided into control group and experimental group.The control group were treated by cyclophosphamide, pirarubicin, vincristine and prednisone and the experiment group were treated on the basis of control group with rituximab.The serum hepcidin, sCD40L, PDGF-BB and LDH levels were compared after treatment.Results Compared with pre-treatment, the serum hepcidin, PDGF-BB and LDH levels were lower( P<0.05), the sCD40L level was higher(P<0.05) post-treatment.The serum hepcidin, PDGF-BB and LDH levels in experimental group post-treatment were lower, sCD40L level was higher than those in control group(P<0.05).Conclusions The rituximab could reduce serum hepcidin, PDGF-BB and LDH levels and elevate serum sCD40L level in patients with malignant lymphadenoma.
